FY2024 EPS Estimates for Adlai Nortye Ltd. (NASDAQ:ANL) Boosted by Analyst

Adlai Nortye Ltd. (NASDAQ:ANL) – Research analysts at Cantor Fitzgerald increased their FY2024 earnings estimates for shares of Adlai Nortye in a report released on Tuesday, April 23rd. Cantor Fitzgerald analyst L. Chen now anticipates that the company will post earnings per share of ($2.41) for the year, up from their previous forecast of ($2.50). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Adlai Nortye’s current full-year earnings is ($2.90) per share.

Adlai Nortye Price Performance

ANL stock opened at $13.75 on Thursday. The firm has a 50-day moving average price of $9.45 and a 200-day moving average price of $9.33. Adlai Nortye has a 12 month low of $7.11 and a 12 month high of $19.30.

Institutional Investors Weigh In On Adlai Nortye

An institutional investor recently raised its position in Adlai Nortye stock. Cantor Fitzgerald L. P. boosted its stake in Adlai Nortye Ltd. (NASDAQ:ANL) by 128.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 40,310 shares of the company’s stock after purchasing an additional 22,644 shares during the period. Cantor Fitzgerald L. P. owned about 0.11% of Adlai Nortye worth $362,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 35.21% of the company’s stock.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.